Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

ZENITH HEALTH CARE LTD.

Healthcare › Pharmaceuticals & Biotechnology
₹3.61
at close · 28 Oct 2026
▲ 0.58 (+19.14%)

Latest filings

  1. September 2026 results: Q2 profit falls, H1 net profit rises 30% · Results
  2. Q2 profit falls 83%, half-year profit rises 30% · Results
  3. Board meeting on Oct 28, 2026 to approve Q2/H1 FY26-27 results · Results
All filings ↓
Ask Nexa about ZENITH HEALTH CARE LTD.

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on BSE, reporting revenue of ₹11 Cr over the trailing twelve months.

Market Cap
₹19 Cr
P / E (TTM)
180.5×
EV / EBITDA
67.2×
Div Yield
—
Growth
-5.2%▼
Revenue 5y CAGR
PAT -59.0% · EBITDA -19.1%
Quality
3.9%·
ROCE (5y median)
ROE 1.1% (5y median) · margin 2.7%
Leverage
0.00·
Debt / Equity · low
Net cash ₹0.37 Cr
Revenue FY21→FY26
0.8×▼
Margin −3.2 pts
₹14 Cr → ₹11 Cr
Cash conversion
3.26×▲
Operating cash ÷ profit · 5 yrs
₹2 Cr on ₹1 Cr
Moves on a normal day
1.16%·
Median daily move
Last 267 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#152/158
P/B#71/163
ROCE#151/183
ROE#141/166
Debt / Equity#1/166
EBITDA margin#161/165
Revenue growth#143/161
Profit growth#156/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
No borrowings on the balance sheet
lower than 79% of its 166 Pharmaceuticals peers
Over 5 years it reported ₹0.66 Cr of profit and ₹2.17 Cr of operating cash — 3.26×
Profit is converting into cash
Concerns
Revenue shrinking over 5 years (−5% a year)
Profit shrinking over 5 years (−59% a year)
Erratic profits — up in only 1 of the last 5 years
Returns on capital 3.9% (5-year median)
#151 of 183 in Pharmaceuticals on the latest reported figures · down from 8.3% in FY21
Heavy working capital — 122 days of cash tied up
Customers are taking longer to pay — 45 → 73 days of receivables
FY21 → FY26

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from ZENITH HEALTH CARE LTD.'s filed financials and exchange disclosures

What does ZENITH HEALTH CARE LTD. do?

ZENITH HEALTH CARE LTD. is a Pharmaceuticals & Biotechnology company listed on BSE.

Is ZENITH HEALTH CARE LTD. profitable?

Yes. Over the trailing twelve months ZENITH HEALTH CARE LTD. reported a net profit of ₹0.01 Cr on revenue of ₹11 Cr.

Does ZENITH HEALTH CARE LTD. pay a dividend?

Not in the latest reported year — ZENITH HEALTH CARE LTD.'s dividend payout for FY26 was nil.

Is ZENITH HEALTH CARE LTD. debt-free?

Yes. It reported no borrowings on its 31 Mar 2026 balance sheet, and ₹0.37 Cr of cash.

Is ZENITH HEALTH CARE LTD. expensive compared with its peers?

On trailing P/E, ZENITH HEALTH CARE LTD. ranks 152 of 158 in Pharmaceuticals — cheaper than 4% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.

How much does the ZENITH HEALTH CARE LTD. share price move in a day?

On a typical session ZENITH HEALTH CARE LTD. moves 1.16% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.

Where can I track ZENITH HEALTH CARE LTD.'s announcements?

Every NSE and BSE filing by ZENITH HEALTH CARE LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.